ID   KTC-1
AC   CVCL_6300
SY   KTC1; KTC1naive
DR   BTO; BTO:0005144
DR   cancercelllines; CVCL_6300
DR   CCRID; 3101HUMSCSP552
DR   CLS; 305113
DR   Cosmic; 683717
DR   Cosmic; 1239967
DR   Cosmic; 2054106
DR   Cosmic; 2755722
DR   IARC_TP53; 21625
DR   Wikidata; Q54900619
RX   CelloPub=CLPUB00144;
RX   PubMed=10946899;
RX   PubMed=18713817;
RX   PubMed=23833040;
RX   PubMed=25675381;
RX   PubMed=29156680;
RX   PubMed=30737244;
CC   Population: Japanese.
CC   Doubling time: ~48 hours (PubMed=10946899).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=29156680).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=29156680; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Asp63Val (c.188A>T); Zygosity=Heterozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): PubMed=18713817; PubMed=30737244
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 12
ST   D18S51: 12,13
ST   D21S11: 29
ST   D3S1358: 14,15
ST   D5S818: 11,12
ST   D7S820: 11
ST   D8S1179: 11,14
ST   FGA: 23,26
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 14,17
DI   NCIt; C6040; Poorly differentiated thyroid gland carcinoma
DI   ORDO; Orphanet_100088; Thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   68Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 23
//
RX   CelloPub=CLPUB00144;
RA   Kurebayashi J., Tanaka K., Yamamoto Y., Okubo S., Sonoo H.;
RT   "Human epidermal growth factor receptor 1 and thrombospondin-1 in
RT   thyroid cancer.";
RL   (In book chapter) Trends in thyroid cancer research. Horizons in cancer research, Vol. 37; Milton C.A. (eds.); pp.89-116; Nova Science Publishers; Hauppauge; USA (2007).
//
RX   PubMed=10946899; DOI=10.1210/jcem.85.8.6732;
RA   Kurebayashi J., Tanaka K., Otsuki T., Moriya T., Kunisue H., Uno M.,
RA   Sonoo H.;
RT   "All-trans-retinoic acid modulates expression levels of thyroglobulin
RT   and cytokines in a new human poorly differentiated papillary thyroid
RT   carcinoma cell line, KTC-1.";
RL   J. Clin. Endocrinol. Metab. 85:2889-2896(2000).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. 3rd, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=25675381; DOI=10.1210/jc.2014-2764; PMCID=PMC4422887;
RA   von Roemeling C.A., Marlow L.A., Pinkerton A.B., Crist A., Miller J.,
RA   Tun H.W., Smallridge R.C., Copland J.A. 3rd;
RT   "Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals
RT   stearoyl CoA desaturase 1 as a novel therapeutic target.";
RL   J. Clin. Endocrinol. Metab. 100:E697-E709(2015).
//
RX   PubMed=29156680; DOI=10.18632/oncotarget.21262; PMCID=PMC5689570;
RA   Antonello Z.A., Hsu N., Bhasin M., Roti G., Joshi M., Van Hummelen P.,
RA   Ye E., Lo A.S., Karumanchi S.A., Bryke C.R., Nucera C.;
RT   "Vemurafenib-resistance via de novo RBM genes mutations and chromosome
RT   5 aberrations is overcome by combined therapy with palbociclib in
RT   thyroid carcinoma with BRAF(V600E).";
RL   Oncotarget 8:84743-84760(2017).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//